

**«Біла селезінка» при волосистоклітинній лейкемії****М. М. Мілосавлевич<sup>2</sup>, Б. С. Тадич<sup>1</sup>, М. М. Грубор<sup>1</sup>, С. В. Матич<sup>1</sup>, М. М. Раделич<sup>1</sup>**<sup>1</sup>Перша хірургічна клініка, медичний факультет Белградського університету,  
<sup>2</sup>Головна лікарня Штефана Високи, Смедеревська Паланка**«White spleen» in hairy cell leukemia****V. M. Milosavljević<sup>2</sup>, B. S. Tadić<sup>1</sup>, N. M. Grubor<sup>1</sup>, S. V. Matić<sup>1</sup>, M. M. Reljić<sup>1</sup>**<sup>1</sup>Clinic for Digestive Surgery of the CCS – First Surgical Clinic, Faculty of Medicine, University of Belgrade,  
<sup>2</sup>General Hospital Stefan Visoki, Smederevska Palanka**Introduction**

The first researches by the haematologist and the first indications regarding Hairy cell leukemia (HCL) date back to the 1923. Since then, there have been numerous studies related to this disease and described in the literature [1, 2]. In 1958. Bouroncle and associates described the leukemic reticuloendotheliosis as a separate entity with a typical (Hairy cell) cell appearance [3].

HCL is a malignant chronic lymphoproliferative disease that covers 2% of all leukemia and occurs four times more often in males than in females. The average age of patients diagnosed with this disease is about 55 years [4, 5]. The disease is manifested by pancytopenia, absence of peripheral lymphadenopathy, enlarged spleen and often absolute monocytopenia. Peripheral blood contains mature B cells with voluminous cytoplasmic projections that resemble hairs. Histologically, HCL cells biopsied from the bone marrow have a cytoplasm that surrounds the nucleus and that way resembles an egg [6].

The most common manifestation of this disease is splenomegaly and occurs in about 96% of patients. Often, splenomegaly becomes symptomatic and manifests as pain in the epigastrium and feeling of flatulence and discomfort in the stomach [7, 8]. In 1984, splenectomy was the method of choice in the treatment of this disease [9]. The start of administration of purine analogues in the treatment of HCL was a revolutionary treatment, with a total response of 85% of patients and survival up to 15 years without a progression [10, 11]. Cladribine and Pentostatin, 2 analogues of purine, are the first line in the treatment of HCL. They are equally effective in encouraging and maintaining of remission. Thanks to its favorable toxicity profile, most hematologists consider that Cladribin is the first line of chemotherapy. Interferon alfa is an option for treatment of this disease during pregnancy, when the treatment is justified. It can also be used as initial treatment in patients with severe pancytopenia or an active infection, in order to improve blood test results and to allow further therapy of purine analogues [12 – 15]. Splenectomy is applied in a patients with massive symptomatic splenomegaly, severe pancytopenia due to cell sequestration, as well as a temporary measure in pregnant women when symptomatology is expressed [15].

In our work, we present a patient who experienced a relapse of the disease after two cycles of chemotherapy, as confirmed by biopsies of the bone marrow. Because of massive



symptomatic splenomegaly, leukocytopenia and thrombocytopenia, the consilium, consisted of surgeons and hematologist, decided to perform a splenectomy.

**Case report**

61 years old patient was admitted to the Clinic for Digestive Surgery – First Surgical Clinic, Clinical Center of Serbia, due to pains in the upper parts of the abdomen, feeling of flatulence, weight and discomfort in the abdomen.

At the admission, we discover that his enlarged spleen was diagnosed 16 years ago, when he was also supposed to have a bone marrow biopsy to which he did not go, and hasn't report to a doctor since then. His first admission to our institution was at the end of 2014 as an emergency case due to abdominal pain and the presence of splenomegaly. After initial diagnostics, he was transferred to the Clinic for Hematology where he was diagnosed with HCL and ordained with chemotherapy (Cladribine). After 6 months, a control biopsy of the bone marrow showed a significant reduction in bone marrow infiltration from 40% to 10%. In July 2015, he got another cycle of the (Cladribine) chemotherapy. The bone marrow biopsy in January 2016 detected a complete haematological remission of the disease in a bone marrow, but there was still a splenomegaly with expressed symptoms. The value of the platelets at the admission to our Clinic were  $38 \times 10^9/L$ . Computerized tomography (CT) confirmed the previous finding of splenomegaly. The length of the spleen in the cranial – caudal direction (longitudinal diameter) was 29.09 cm, while its transversal diameter was 21.81 cm (Fig. 1). Due to the existence of a massive splenomegaly (> 20 cm in the cranial – caudal direction) we decided for the classic splenectomy. After surgery, the weight of the spleen was 1950 gr. The macroscopic preparation of the spleen was largely covered with a light-colored hyaline capsule with a thickness of 5–15 mm (Fig. 2).

Histopathological examination found that splenic architecture was changed to the account of highly expanded red pulp with very rare white pulp residues, and that corresponds to infiltrative leukemic infiltration. This examination also the presence of Residual splenic disease in hairy cell leukaemia after treatment with chemotherapy (Cladribin). The infiltrates are confined to the red pulp. And Hyaline perisplenitis known as “icing sugar spleen“ with capsule thickening ranging 5 to




*Fig. 1. Preoperative imaging (CT), Cranicaudal and transversal diameter of the spleen.*



*Fig. 2. The macroscop preparation of the spleen.*



*Fig. 3. Hairy cell infiltrate and blood lakes are seen in splenic parenchyma.*



*Fig. 4. Immunohistochemical examination, immunoreactivity for DAB 44 in splenic hairy cell infiltrate.*

15mm in this patient. Hairy cell infiltrate and blood lakes are seen in splenic parenchyma (Fig. 3).

Additional immunohistochemical examination confirmed strong, diffuse immunoreactivity for CD20. And Immunoreactivity for DAB 44 in splenic hairy cell infiltrate (Fig. 4).

### Discussion

Introduction of purine analogues in the treatment of HCL significantly contributed to improving the patients' surviv-

al. In some HCL patients, a long perennial remission can be achieved only with the usage of the purine analogues and without additional therapy [10]. Some authors believe that the length of the disease-free interval is related to achieving a complete response to therapy [15, 16]. Although HCL is an incurable disease, with current therapy, patients can achieve permanent remission without further continuous application of therapy, except in cases of symptomatic relapse [17].

Despite the complete therapeutic response after two cycles of chemotherapy, as confirmed by biopsies of the bone marrow, a permanent splenomegaly remained with pronounced symptoms. By agreement with a surgeon and hematologist, the consilium decided to perform splenectomy. Histopathological examination and immunohistochemical verification confirmed the residual HCL in the spleen. It is not clear if splenomegaly would have spontaneously regress anyway, but after a histopathological examination, it turned out that performing of splenectomy as a strategy proved to be the real therapeutic option. Patients with complete therapeutic response should have hemoglobin > 110 g/L, no additional transfusion, platelets >  $100 \times 10^9/L$  and neutrophils >  $1500/\mu L$  [18]. After surgery, and just before hospital release, the patient we operated on had hemoglobin 108 g / L, platelets  $318 \times 10^9/L$  and neutrophils  $2100/\mu L$ . In patients with HCL, the most common cause is infection. These patients have neutrophilia and monocyto-

penia, so bacterial, viral and opportunistic infections are expected. Purine analogues provide long-term suppression of immune system cells and induce prolonged neutropenia [19].

It is very important to inform and educate patients about infections prevention. The results of the use of specific preventive options has not been confirmed in some controlled studies, but the practice differs from patient to patient, thus the strategies of prevention and treatment vary [18, 20].

After splenectomy, antibiotic prophylaxis, as well as post-operative vaccination, were performed in accordance with the current directives and guidelines for the treatment and prevention of postsplenectomy infections [21, 22]. After surgery, the patient is in remission for 2 years. His period of monitoring and remission continues.

### Conclusion

Although splenectomy does not represent the first measure of treatment of HCL, from this case can be concluded that even in the era of the use of purine analogues, splenectomy can be of great benefit in the treatment and a determinant of its success. From the literature can be concluded that HCL has many unusual manifestations of the disease and it is necessary to continuously monitor and improve the guidelines and strategies for the treatment, and guidelines should also be of great benefit in improving the treatment and should not be used for refusal of the necessary diagnostic and therapeutic treatment options.

### References

- Ewald O. Die leukämische retikuloendotheliose. *Dtsch Arch Klin Med.* 1923;142:222–8.
- Fieschi A. Istioleucemia. *Haematologica* 1942;24:751–74.
- Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. *Blood.* 1958;13(7):609–30. PMID: 13560561.
- Mey U, Strehl J, Gorschluter M, Ziske C, Glasmacher A, Pralle H, et al. Advances in the treatment of hairy-cell leukaemia. *Lancet Oncol.* 2003 Feb;4(2):86–94. PMID: 12573350.
- Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. *Curr Treat Options Oncol.* 2014 Jun;15(2):187–209. doi: 10.1007/s11864-014-0285-5.
- Pande P, Yelikar BR, Kumar UM. A hairy cell leukaemia variant – a rare case report. *J Clin Diagn Res.* 2013 Feb;7(2):358–60. doi: 10.7860/JCDR/2013/5169.2768.
- Gedik E, Girgin S, Aldemir M, Keles C, Tuncer MC, Aktas A. Non-traumatic splenic rupture: report of seven cases and review of the literature. *World J Gastroenterol.* 2008 Nov 21;14(43):6711–6. doi: 10.3748/wjg.14.6711
- Lavrenkov K, Krepel-Volsky S, Levi I, Ariad S. Low dose palliative radiotherapy for splenomegaly in hematologic disorders. *Leuk Lymphoma.* 2012 Mar;53(3):430–4. doi: 10.3109/10428194.2011.614708.
- Habermann TM, Rai K. Historical treatments of hairy cell leukemia, splenectomy and interferon: past and current uses. *Leuk Lymphoma.* 2011 Jun;52 Suppl 2:18–20. doi: 10.3109/10428194.2011.573033.
- Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. *Br J Haematol.* 2009 Jun;145(6):733–40. doi: 10.1111/j.1365-2141.2009.07668.x.
- Grever MR. How I treat hairy cell leukemia. *Blood.* 2010 Jan 7;115(1):21–8. doi: 10.1182/blood-2009-06-195370.
- Matutes E, Martinez-Trillos A, Campo E. Hairy cell leukaemia-variant: Disease features and treatment. *Best Pract Res Clin Haematol.* 2015 Dec;28(4):253–63. doi: 10.1016/j.beha.2015.09.002.
- Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C, Committee EG. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v100–7. doi: 10.1093/annonc/mdv200.
- Naing PT, Acharya U. Cancer, Leukemia, Hairy Cell. *StatPearls [Internet].* Treasure Island (FL): StatPearls Publishing; 2018 Jan–2018 May.
- Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. *Blood.* 2014 Jan 9;123(2):177–83. doi: 10.1182/blood-2013-06-508754.
- Golomb HM. Fifty years of hairy cell leukemia treatments. *Leuk Lymphoma.* 2011 Jun;52 Suppl 2:3–5. doi: 10.3109/10428194.2011.565094..
- Grever MR. Hairy cell: young living longer but not cured. *Blood.* 2014 Jan 9;123(2):150–1. doi: 10.1182/blood-2013-11-538280.
- Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, et al. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. *Ann Hematol.* 2014 Dec;93(12):1977–83. doi: 10.1007/s00277-014-2140-y.
- Tadmor T. Purine analog toxicity in patients with hairy cell leukemia. *Leuk Lymphoma.* 2011 Jun;52 Suppl 2:38–42. doi: 10.3109/10428194.2011.565097.
- Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with hematological and solid malignancies, 2014. *Intern Med J.* 2014 Dec;44(12b):1350–63. doi: 10.1111/imj.12599.
- Buzele R, Barbier L, Sauvanet A, Fantin B. Medical complications following splenectomy. *J Visc Surg.* 2016 Aug;153(4):277–86. doi: 10.1016/j.jvisurg.2016.04.013.
- Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. *Lancet.* 2011 Jul 2;378(9785):86–97. doi: 10.1016/S0140-6736(10)61493-6.